Skip to main content

CUSTOMISED DNA-BASED NANOCARRIERS TO BOOST HEART HEALING

PCI2023-143438

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Afrontar las Prioridades de Nuestro Entorno
Subprogram Subprograma Estatal de Internacionalización
Call Proyectos Programación Conjunta Internacional
Call year 2023
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION SANITARIA ARAGON

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

DNA-based nanocarriers to sequester altered microRNAs in cardiac dysfunction

  • Postigo, Alejandro
  • Hernández-Bellido, Natalia
  • Sánchez-Barat, Marcos
  • García-Mendívil, Laura
  • Pueyo, Esther
  • Barrio, Jesús del
  • Hernández-Ainsa, Silvia
  • Ordovás, Laura
MicroRNAs (miRs) play a critical role in modulating gene expression across biological processes, including cardiac aging and disease. As such, miRs have demonstrated therapeutic potential in several cardiac conditions. Efficient delivery of miR therapies to cardiac tissue is crucial for effective gene therapy and DNA-based nanocarriers (DNCs), based on Watson-Crick-Franklin highly specific base-pair recognition, have emerged as a promising, biocompatible alternative to viral-based methods. Here, DNCs designed to modulate miR levels as a potential treatment for cardiac dysfunction are presented. Specifically, the DNCs target miR-24-2, which inhibits SERCA2 gene. In humans, the reduction of SERCA2 activity is a hallmark of heart failure and is altered in cardiac aging. The assembled DNCs bearing anti-miR-24-2-5p sequences effectively restore intracellular levels of SERCA2 in a HEK293 cell model. The DNCs proper assembly is thoroughly verified, while their stability and miR-capture ability are demonstrated in vitro. The DNCs exhibit successful internalization into HEK293 and modest uptake into human cardiomyocytes. SERCA2 restoration by DNCs is significantly influenced by the miR-capture sequence layout, underscoring the importance of precise design for optimal biological outcomes. This study highlights the potential of DNCs in cardiac therapies, a previously unexplored avenue for addressing cardiac dysfunction., Authors acknowledge the following funding: grant LMP128_21 by Gobierno de Aragón, grant PID2020-113003GB-I00 funded by MICIU/AEI/10.13039/501100011033, PID2022-139859OB-I00 funded by MICIU/AEI/10.13039/501100011033 and ERDF, UE and Research Group grants (E47_23R and T39_23R) by Gobierno de Aragón. This study was also supported by MCIN with funding from European Union NextGenerationEU (PRTR-C17.I1). Authors also acknowledge DNABEATS project, Joint Transnational Call 2022 of M-ERA.NET 3, (Horizon 2020 grant agreement No 958174) and supported by grants PCI2023-143390 and PCI2023-143438 funded by MICIU/AEI/10.13039/501100011033 and cofounded by EU. N.H.-B. and M.S.-B. were funded by Gobierno de Aragón fellowships CPB_09_20 and CPB_14_22, respectively. The authors would like to acknowledge the Servicio General de Apoyo a la Investigación-SAI (Universidad de Zaragoza) and Servicios Científico-Técnicos (microscopía, UNATI, y citometría) of CIBA (IISA-IACS-Universidad de Zaragoza) for their support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Nanotechnology-driven heart targeting to fulfil the potential of cardiac microRNA therapies

  • Hernández-Bellido, Natalia
  • Hernández-Ainsa, Silvia
  • Köhler, Ralf
  • Ordovás, Laura
MicroRNAs play a crucial role in regulating gene expression in most biological processes, including cardiac disease, regeneration and aging. They are therefore an attractive and novel therapeutic option, and extensive research in small animal models has demonstrated this potential in the heart. While the therapeutic outcomes obtained in large animal models are also promising, far fewer studies have been conducted in this species. Even fewer microRNA therapeutics have reached clinical trials, only CDR132L and MRG-110. This highlights a bottleneck in their development primarily associated with challenges in their in vivo delivery, specifically due to their limited stability and ability to penetrate the heart tissue., This review aims to describe the current state of development of cardiac microRNA therapies in relation to these challenges and to provide a comparative overview of the progress made in overcoming them. A special focus is set on the application of pharmaceutical nanotechnology and the development of targeted delivery strategies to the heart. These approaches have been tested primarily in small animal models and have shown to improve the cardiac penetration, accumulation and/or stability and of microRNAs and, therefore, their therapeutic efficacy compared to naked delivery. Notably, the latter is typically the method of choice in late preclinical research and early clinical trials. Consequently, targeted microRNA nanotherapies could be pivotal in overcoming the current bottleneck and realizing the therapeutic potential of microRNAs in the heart., In conclusion, this review offers an outlook of the future applicability of microRNA therapies leveraging the latest advances in non-viral targeted delivery with nanocarriers., LO acknowledges the support of grant PID2022-139859OB-I00 funded by MCIU/AEI/10.13039/501100011033 and ERDF, EU and grant PROY_B08_24 and BSICoS group T39_23R funded by Gobierno de Aragón. LO and SHA also acknowledge DNABEATS project, Joint Transnational Call 2022 of M-ERA.NET 3, (Horizon 2020 grant agreement No 958174) and supported by grants PCI2023-143390 and PCI2023-143438 funded by MICIU/AEI/10.13039/501100011033 and cofounded by EU. SHA acknowledges support by grant PID2023-147656OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by ERDF, UE, and MCIN with funding from the European Union NextGenerationEU (PRTR-C17.I1) promoted by the Government of Aragón. N.H-B was supported by the predoctoral (CPB_09_20) and mobility (MVB_03_23) fellowships funded by Gobierno de Aragón., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

DNA-Based Nanocarriers to Sequester Altered microRNAs in Cardiac Dysfunction

  • Postigo, Alejandro
  • Hernández-Bellido, Natalia
  • Sánchez-Barat, Marcos
  • García-Mendívil, Laura
  • Pueyo, Esther
  • del Barrio, Jesús
  • Hernández-Ainsa, Silvia
  • Ordovás, Laura
MicroRNAs (miRs) play a critical role in modulating gene expression across biological processes, including cardiac aging and disease. As such, miRs have demonstrated therapeutic potential in several cardiac conditions. Efficient delivery of miR therapies to cardiac tissue is crucial for effective gene therapy and DNA‐based nanocarriers (DNCs), based on Watson‐Crick‐Franklin highly specific base‐pair recognition, have emerged as a promising, biocompatible alternative to viral‐based methods. Here, DNCs designed to modulate miR levels as a potential treatment for cardiac dysfunction are presented. Specifically, the DNCs target miR‐24‐2, which inhibits SERCA2 gene. In humans, the reduction of SERCA2 activity is a hallmark of heart failure and is altered in cardiac aging. The assembled DNCs bearing anti‐miR‐24‐2‐5p sequences effectively restore intracellular levels of SERCA2 in a HEK293 cell model. The DNCs proper assembly is thoroughly verified, while their stability and miR‐capture ability are demonstrated in vitro. The DNCs exhibit successful internalization into HEK293 and modest uptake into human cardiomyocytes. SERCA2 restoration by DNCs is significantly influenced by the miR‐capture sequence layout, underscoring the importance of precise design for optimal biological outcomes. This study highlights the potential of DNCs in cardiac therapies, a previously unexplored avenue for addressing cardiac dysfunction.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Nanotechnology-driven heart targeting to fulfil the potential of cardiac microRNA therapies

  • Hernández-Bellido, Natalia
  • Hernández-Ainsa, Silvia
  • Köhler, Ralf
  • Ordovás, Laura
MicroRNAs play a crucial role in regulating gene expression in most biological processes, including cardiac disease, regeneration and aging. They are therefore an attractive and novel therapeutic option, and extensive research in small animal models has demonstrated this potential in the heart. While the therapeutic outcomes obtained in large animal models are also promising, far fewer studies have been conducted in this species. Even fewer microRNA therapeutics have reached clinical trials, only CDR132L and MRG-110. This highlights a bottleneck in their development primarily associated with challenges in their in vivo delivery, specifically due to their limited stability and ability to penetrate the heart tissue. This review aims to describe the current state of development of cardiac microRNA therapies in relation to these challenges and to provide a comparative overview of the progress made in overcoming them. A special focus is set on the application of pharmaceutical nanotechnology and the development of targeted delivery strategies to the heart. These approaches have been tested primarily in small animal models and have shown to improve the cardiac penetration, accumulation and/or stability and of microRNAs and, therefore, their therapeutic efficacy compared to naked delivery. Notably, the latter is typically the method of choice in late preclinical research and early clinical trials. Consequently, targeted microRNA nanotherapies could be pivotal in overcoming the current bottleneck and realizing the therapeutic potential of microRNAs in the heart. In conclusion, this review offers an outlook of the future applicability of microRNA therapies leveraging the latest advances in non-viral targeted delivery with nanocarriers.